摘要
目的观察小剂量利妥昔单抗联合重组人血小板生成素治疗ITP的疗效和安全性。方法 14例ITP患者采用利妥昔单抗100 mg qw,4次;重组人血小板生成素(rhTPO)3 000μg/kg·d-1,ih,14 d。治疗前后定期监测外周血血小板计数、血清免疫球蛋白,流式细胞术检测淋巴细胞亚群。结果 14例患者中CR 7例,R 6例,NR 1例,总有效率93%。结论小剂量利妥昔单抗联合重组人血小板生成素治疗ITP疗效确切。
Objective To observe the clinical effects and safety of low dose of rituximab combined re- combinant human thrombopoietin in treatment of primary immune thrombocytopenia. Methods 14 patients with ITP given with low dose of rituximab 100 mg, once a week ,four consecutive weeks, and given with recom- binant human thrombopoietin（rhTPO） 3 000 μg/kg subcutaneously once daily for 14 days. Platelet counts, serum immune globin and lymphocyte subgroups were monitored before and after therapy. Results There were 7 cases of CR,6 cases of R,1 case of NR. The total effective rate was 93%. Conclusion Low dose of rituximab combined recombinant human thrombopoietin could be satisfactory.
出处
《血栓与止血学》
2014年第2期68-70,73,共4页
Chinese Journal of Thrombosis and Hemostasis
